|
ACCEPTED
WORLDWIDE AND BACKED BY OVER 50 YEARS
OF CLINICAL EXPERIENCE |
| THE
FIRST ANTI-D IMMUNE GLOBULIN PRODUCT IN
THE WORLD LICENSED FOR THE TREATMENT OF
ITP AND TODAY, WinRho SDFTM IS SOLD IN MANY
COUNTRIES WORLDWIDE. OVER TWO MILLION DOSES
HAVE BEEN ADMINISTERED OF DATE. |
|
SAFETY |
|
•
Twice
PCR Tested: First PCR Test on plasma and
second PCR Test on Plasma pool before
the start of fractionation for the absence
of HIV, HCV & HBV
•
Solvent detergent
step validated to inactivate lipid enveloped
viruses such as HIV, Hepatitis B
and Hepatitis C1
•
20 Nanometer filter validated to remove
non-lipid enveloped viruses such as hepatitis
A and
B19 Parvovirus1 |
|
The
strict precaution taken in the manufacture
of winRho SDFTM Dramatically
reduce the potential for viral transmission. |
|
PURITY |
|
•
No mercurial Preservative1
•
Low in contamination IgA1 |
|
CONVENIENCE |
|
•
Because of its high
level of purity WinRho SDFTM
can be administered intravenously or
intramuscularly1.
•
Win Rho SDFTM is available
in two convenient dosage format :-
300 mcg (1500 IU), 1000 mcg (5000
IU). |
|
Dosage
in ITP
50
to 75 mcg/kg body weight. |
|
Effectiveness |
|
•
Licensed for the
prevention of hemolytic disease of the
newborn
•
Licensed for the treatment of Immune Thrombocytopenic
Purpura (ITP) |
|
Schedule
D Drug |
| 1.
Product Monograph, WinRho SDFTM
, Cangene corporation. August 24, 1998.
2. Tarantino MD, Goldsmith G: Treatment
of acute immune thrombocytopenic purpura.
Seminars in Hematology: Vol35, No 1, Suppl
1 (January), 1998: pp 28-35
3. Package Insert, Venoglobulin-S®,
5% Solution, Alpha Therapeutic Corporation,
august 1999.
4. Current Market research Data |
|
Back
|
top
|
| Click
Here For More Information |
| |
